Updates are available Correction dated 2021-07-27
Click to view Correction: https://doi.org/10.1038/s41421-021-00308-8
-
Authors
Tu, Wen Juan
McCuaig, Robert D.
Melino, Michelle
Rawle, Daniel J. http://orcid.org/0000-0001-7248-0101
Le, Thuy T.
Yan, Kexin
Suhrbier, Andreas http://orcid.org/0000-0001-8986-9025
Johnston, Rebecca L.
Koufariotis, Lambros T.
Waddell, Nicola http://orcid.org/0000-0002-3950-2476
Cross, Emily M.
Tsimbalyuk, Sofiya
Bain, Amanda
Ahern, Elizabeth
Collinson, Natasha
Phipps, Simon
Forwood, Jade K.
Seddiki, Nabila
Rao, Sudha
-
Funding
Funding for this research was provided by:
QIMR Berghofer Medical Research Institute
Department of Health | National Health and Medical Research Council (APP1173880)
- License Information
-
More Information
Article History
Received: 27 December 2020
Accepted: 24 April 2021
First Online: 24 May 2021
Change Date: 27 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41421-021-00308-8
Conflict of interest
: R.L.J. and L.T.K. declare no competing interests. N.W. is a co-founder, equity holder, and board member of genomiQa Pty Ltd, a spin-out company from QIMR Berghofer. In accordance with NHMRC policy and our ethical obligations as researchers, we report that S.R., W.J.T., R.D.M. have a equity in EpiAxis Therapeutics Pty Ltd. We have in place a plan for managing any potential conflicts arising from that involvement.
